Illumina employees have been showing their commitment to early cancer detection and advancing research and treatment by ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina is a prominent entity in the genomic sequencing market, providing advanced DNA sequencing ... The favorable court ...

Customers will also share data from studies using the technologies including an effort to investigate protein biomarkers for ...

The Human Genome Project described the first (almost) complete reference genome, but it didn’t say much about human variation ...

Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: ...

Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ETCorporate ParticipantsSalli Schwartz - Vice President of ...

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP ...

2024 / Illumina employees have been showing their commitment to early cancer detection and advancing research and treatment by getting involved in the company's recently concluded Steps Against ...